上市公司資料
 
深圳市海普瑞藥業集團股份有限公司 股票代號:  09989
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 集團網址: http://www.hepalink.com
損益表
  2024/12
RMB(K$)
變動 2023/12
RMB(K$)
2022/12
RMB(K$)
營業額5,258,919-3.168%5,430,9747,151,039
經營溢利/(虧損)868,049--(480,383)928,313
特殊項目--------
攤佔聯營公司及共同控制公司溢利/(虧損)(141,820)--(447,951)(98,462)
稅前溢利/(虧損)726,229--(928,334)829,851
稅項(101,311)--126,175(114,816)
少數股東權益21,82415.465%18,90112,390
股東應佔溢利/(虧損)646,742--(783,258)727,425
 
淨利息收入/(支出)(93,426)--(183,698)(181,103)
折舊與攤銷334,909-11.364%377,848312,007
董事酬金----8,3768,893
 
每股盈利/(虧損)(仙)44.000--(53.000)50.000
每股派息(仙)25.000--0.00010.000
 
派息比率(%)56.818%----20.000%
每股帳面資產淨值($)9.74119.973%8.1198.391
主要財務比率
  2024/12
RMB(K$)
變動 2023/12
RMB(K$)
2022/12
RMB(K$)
經營邊際利潤率(%)16.506%--(8.845)%12.982%
利息盈利率(x)6.144----4.528
資產回報率(%)3.539%--(3.914)%3.644%
股東資金回報率(%)5.376%--(6.466)%6.132%

 

Copyright © 2025 ET Net Limited. All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.